Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Outlook Therapeutics | 2026 | Post Ipo Debt | $18.4M | Iselin |
| Alto Neuroscience | 2026 | Post Ipo Equity | $120.0M | Los Altos |
| Solid Biosciences | 2026 | Post Ipo Equity | $240.0M | Charlestown |
| Beam Therapeutics | 2026 | Post Ipo Debt | $100.0M | Cambridge |
| Talkiatry | 2026 | Series D | $210.0M | New York |
| Xilio Therapeutics | 2026 | Post Ipo Equity | $40.0M | Waltham |
| Nautilus Biotechnology | 2026 | Grant | $1.6M | San Carlos |
| Yarrow | 2025 | Series Unknown | $200.0M | New York |
| Contineum Therapeutics | 2025 | Post Ipo Equity | $99.2M | San Diego |
| Crescent Biopharma | 2025 | Post Ipo Equity | $185.0M | Rockville |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Outlook Therapeutics | Post Ipo Debt | $18.4M | Iselin, United States |
| 27 | Alto Neuroscience | Post Ipo Equity | $120.0M | Los Altos, United States |
| 28 | Solid Biosciences | Post Ipo Equity | $240.0M | Charlestown, United States |
| 29 | Beam Therapeutics | Post Ipo Debt | $100.0M | Cambridge, United States |
| 30 | Talkiatry | Series D | $210.0M | New York, United States |
| 31 | Xilio Therapeutics | Post Ipo Equity | $40.0M | Waltham, United States |
| 32 | Nautilus Biotechnology | Grant | $1.6M | San Carlos, United States |
| 33 | Yarrow | Series Unknown | $200.0M | New York, United States |
| 34 | Contineum Therapeutics | Post Ipo Equity | $99.2M | San Diego, United States |
| 35 | Crescent Biopharma | Post Ipo Equity | $185.0M | Rockville, United States |
Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Talkiatry provides virtual mental healthcare services covered by insurance, connecting patients with licensed psychiatrists.
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Nautilus Biotechnology is a life sciences company that develops a platform for analyzing and quantifying the human proteome.
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.
Hyperfine makes MRI accessible to every patient regardless of income or resources.
TELA Bio is a life science company that specializes in soft tissue reconstruction.
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.
PepGen is empowering nucleic acid therapeutics to go the distance.
Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration.
DarioHealth is a digital therapeutics company engaged in the development and commercialization of patented and proprietary technology.
Perceptive Advisors has invested in 128 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 21 different industry categories.
Among tracked funding rounds, Cidara Therapeutics received $339.0M in a Grant round. Perceptive Advisors's total known invested capital is $9.5B.
Perceptive Advisors's average investment size is $101.5M across its portfolio of 128 companies.
Recent Perceptive Advisors portfolio additions include Outlook Therapeutics, Alto Neuroscience, Solid Biosciences, Beam Therapeutics, Talkiatry. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors